GH secretagogues stimulate your own pituitary gland to produce and release GH in natural pulsatile patterns — they work with your body's existing feedback regulation. Exogenous recombinant HGH bypasses this feedback entirely: you inject GH directly, suppressing your pituitary's own production and disrupting the normal hypothalamic-pituitary axis. Secretagogues produce physiologic GH levels (avoiding supraphysiologic side effects like acromegaly) and preserve your pituitary's responsiveness over time. The trade-off: lower peak GH levels than direct HGH injection. Secretagogues like Sermorelin are FDA-approved for GH deficiency; recombinant HGH is also FDA-approved for specific indications but carries significantly higher regulatory and safety concern when used off-label for performance.

IGF-1 LR3 has compelling mechanistic and animal-model evidence for muscle hypertrophy — it activates every major anabolic pathway (mTOR, satellite cells, glucose uptake, anti-catabolism). The problem is robust human performance evidence is sparse, and the risk profile is serious. The primary dangers: hypoglycemia (IGF-1 drives glucose into cells like insulin — dosing errors can cause acute hypoglycemia), and the theoretical cancer promotion risk (IGF-1 signaling drives cellular proliferation broadly, not just in muscle). People with pre-existing cancers or cancer risk factors should be particularly cautious. It's a research compound used in cell biology, not approved for human therapeutic injection for athletic purposes.

Myostatin (GDF-8) is a TGF-β family protein produced in muscle that acts as the body's genetic brake on muscle mass — it evolved to prevent muscles from growing too large. When myostatin is absent (genetic mutation in humans and cattle), muscles grow 2–3× normal size. ACE-031 is a soluble decoy receptor that captures myostatin (and activin A) before it can signal in muscle. The human trial data is genuinely impressive — a single dose increased lean mass 3.3% within 4 weeks in DMD patients. The major clinical barriers so far have been off-target effects (telangiectasias, bleeding), suggesting the activin A blockade causes vascular side effects. Next-generation myostatin-specific antibodies (which avoid activin inhibition) are in active development to solve this.

MK-677 has the most robust long-term human safety data of any research-grade GH secretagogue — a 2-year Phase II trial in elderly subjects showed it was well-tolerated with the primary concern being insulin resistance (fasting glucose elevation in some subjects). Other documented effects include water retention, appetite increase (~30–40%), and fatigue at higher doses. The critical caveat: it has NOT been FDA-approved for use. All published trials are in the context of GH deficiency or aging-related IGF-1 decline, not healthy young athletes. The insulin resistance concern is particularly relevant for anyone predisposed to type 2 diabetes. Its oral convenience makes it popular, but it's still an investigational compound, and quality of unregulated supply is unknown.

Neither BPC-157 nor TB-500 directly drives muscle hypertrophy the way GH secretagogues or IGF-1 do. Their primary muscle-building contribution is indirect but practically significant: they accelerate recovery from training stress, reduce the risk of connective tissue injuries (tendons, ligaments) that limit training, and in BPC-157's case, upregulate GH receptor expression to amplify the anabolic response to GH. For anyone training at high volumes, reducing recovery time between sessions and preventing/treating minor injuries can substantially increase total training volume over time — which is ultimately the driver of hypertrophy. TB-500 also reduces muscle fibrosis post-injury, preserving functional quality of repaired muscle tissue.

The regulatory landscape is complex and varies by country. Sermorelin is FDA-approved — it can be legally prescribed. MK-677 is in clinical trials but not FDA-approved; it exists in a legal gray area. IGF-1 LR3, MGF, ACE-031, CJC-1295, Ipamorelin, GHRP-6, BPC-157, and TB-500 are all research compounds — not approved for human therapeutic use in the US. Most are prohibited in competitive sports by WADA. Obtaining them outside a licensed clinical context means buying from research chemical suppliers with no pharmaceutical-grade quality assurance. The FDA has also issued warnings about compounded CJC-1295 and related peptides. Anyone considering these compounds should consult a sports medicine physician and fully understand both the legal status in their jurisdiction and the evidence limitations.